A court battle between two of the nation’s largest biotechs — Regeneron Pharmaceuticals and Amgen — is testing the legal limits of how far drugmakers can go in using patents to thwart competition. And the case is being closely watched by companies that sell biosimilar medicines amid concerns that the U.S. patent system is being
Kazia to receive USD $1 million from Vivesto for the intellectual property and trademark assets rights to the oncology drug candidate, Cantrixil SYDNEY, March 31, 2025 /PRNewswire/ — Kazia Therapeutics Limited (NASDAQ: KZIA) (“Kazia” or “the Company”), an oncology-focused drug development company, today announced the sale of all intellectual property and trademarks rights to Cantrixil
The company is focused on developing treatments for acute central nervous system injuries. Credit: Jo Panuwat D/Shutterstock. The US Patent and Trademark Office (USPTO) has allowed two new patents for Remedy Pharmaceuticals’ Cirara to treat large hemispheric infarction (LHI). The allowances encompass a claim for using Cirara’s active ingredient, glyburide, to treat LHI patients with